Biotechnology

Kamada

Kamada released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 45.24 M (forecast USD 45.28 M), actual EPS USD 0.07 (forecast USD 0.115)

Kamada to Release FY2026 Q1 Earnings on May 13 Pre-Market EST, Forecast Revenue USD 47.99M, EPS USD 0.115

Kamada released FY2025 Annual Earnings on March 11 Pre-Market EST, actual revenue USD 180.46 M (forecast USD 180.51 M), actual EPS USD 0.3499 (forecast USD 0.3675)

Kamada released FY2025 Q4 earnings on March 11 Pre-Market (EST), actual revenue USD 44.68 M (forecast USD 45.25 M), actual EPS USD 0.06 (forecast USD 0.0775)

Kamada to Release FY2025 Q4 Earnings on March 11, Pre-Market EST; Forecast Revenue USD 45.7 M, EPS USD 0.0775

Kamada released FY2025 Q3 earnings on November 10 Pre-Market (EST), actual revenue USD 47.01M (forecast USD 46.67M), actual EPS USD 0.09 (forecast USD 0.0925)

Kamada released FY2025 9 Months earnings on November 10 Pre-Market EST, actual revenue USD 135.78 M, actual EPS USD 0.29

Kamada to Release FY2025 Q3 Earnings on November 10, Pre-Market EST; Forecast Revenue USD 46.55 M, EPS USD 0.0925

Kamada released FY2025 Semi-Annual earnings on August 13 Pre-Market (EST), actual revenue USD 88.77 M, actual EPS USD 0.19

Kamada released FY2025 Q2 earnings on August 13 Pre-Market EST, actual revenue USD 44.75 M (forecast USD 46.41 M), actual EPS USD 0.13 (forecast USD 0.09)

Kamada to Release FY2025 Q2 Earnings on August 13 Pre-Market EST, Forecast Revenue USD 46.71 M, EPS USD 0.09

Kamada Ltd. commits to uninterrupted operations and product supply amid Middle East changes

Kamada Ltd. Reports 17% Q1 Revenue Growth to $44 Million

Benchmark Maintains Kamada's Buy Rating with a Target Price of $15

Kamada released FY2025 Q1 earnings on May 14 Pre-Market EST, actual revenue USD 44.02 M (forecast USD 42.78 M), actual EPS USD 0.07 (forecast USD 0.0675)

Kamada Ltd. Introduces Rare Disease Product Portfolio

Kamada Ltd. Reports 17% Q1 Revenue Growth and Expands Plasma Collection Business

Kamada Ltd forecasts EPS of 7 cents

Kamada to release FY2025 Q1 earnings on May 14 Pre-Market EST, forecast revenue USD 42.01 M, EPS USD 0.0675

Kamada Ltd. Launches CMV Management Study Program

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

FULC

KMDA

CING

DRTS

MSFT

This week, the biotech sector saw FDA approvals for Philips' AI ultrasound and Lupin's oncology/ophthalmology drugs, while Kamada gained approval for a rabies testing lab. Fulcrum halted its sickle cell program due to malignancy risks, and Cingulate received an FDA complete response letter for its ADHD drug. Key deals included ResMed acquiring Noctrix Health, Mayo Clinic partnering with Microsoft on healthcare AI, and Alpha Tau collaborating with Tolmar for prostate cancer therapy.

- This week, the U.S. biotech sector experienced significant regulatory activity, including FDA approvals for several therapies, study halts, and strategic collaborations.  
- Notable approvals included Philips' Elevate Plus for ultrasound and Lupin's dual FDA approvals in oncology, while Fulcrum Therapeutics halted its Pociredir program due to safety concerns.  
- Positive clinical trial data was reported across various cancer treatments, demonstrating advancements and potential in key therapeutic areas.

rttnews

NOVARTIS AG

Fulcrum Therapeutics

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Koninklijke Philips Elect

Resmed

Cingulate

Alpha Tau Medical

Microsoft

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals

United Imaging Healthcare

Bluejay Diagnostics

Koninklijke Philips N.V.

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM)

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

Kamada Ltd. announced that the U.S. FDA has approved its new in-house rabies virus neutralization testing laboratory. This approval allows Kamada to conduct specialized tests internally, supporting its commercial product KEDRAB and clinical programs while improving quality control and efficiency. The company aims to reduce reliance on external facilities. Following the announcement, Kamada's stock (KMDA) showed slight movement, closing at $7.81.

nasdaq

Nasdaq

Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory

Kamada shares are trading lower after the company reported worse-than-expected Q1 financial results.

benzinga_article

GOOGL

ORCL

NVDA

GOOG

VERI

NVDU

ORCX

GGLL

Veritone (NASDAQ:VERI) reported Q1 2026 revenue of $20.3 million, a slight decrease from the previous year. The company announced strategic partnerships with Google, Nvidia, and Oracle to enhance its AI services. Veritone maintains a revenue guidance of $130 to $145 million for 2026, driven by growth in VDR and public sector segments. The company aims for operating profitability by Q4 2026, focusing on cost optimization and leveraging AIware's capabilities. Operational highlights include the expansion of Veritone's Data Marketplace and collaborations with media and government sectors.

- Veritone reported Q1 2026 revenue of $20.3 million, a slight decline, primarily due to decreased managed services despite stable software product sales.  
- The company established key strategic partnerships with Google, Nvidia, and Oracle to enhance its AI capabilities and maintain a revenue guidance of $130 to $145 million for 2026, driven by a strong pipeline in the VDR and public sectors.  
- Management aims for operating profitability by Q4 2026, focusing on cost optimization and leveraging strategic partnerships to support growth.

Alphabet

Oracle

NVIDIA

Alphabet - C

Veritone

Direxion Daily NVDA Bull 2X Shares

Defiance Daily Target 2X Long ORCL ETF

Direxion Daily GOOGL Bull 2X Shares

NVIDIA Corporation

ORACLE CORP DEPOSITARY SH REP 1/2000TH PFD SER D

Veritone Q1 2026 Earnings Call: Complete Transcript

SBIO

LABU

Kamada (KMDA) will announce its Q1 earnings on May 13th, with a consensus EPS estimate of $0.12 (+71.4% Y/Y) and revenue estimate of $48.39M (+10.0% Y/Y). The company has a history of beating EPS and revenue estimates 75% of the time over the past two years.

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

VG Health

iShares Global Healthcare

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Kamada Q1 2026 earnings preview

Kamada Ltd. (NASDAQ:KMDA) experienced a significant drop in short interest, falling 32.5% to 109,877 shares as of April 15. The short-interest ratio is 3.3 days, with 0.3% of shares sold short. The stock traded at $8.15, with a market cap of $468.71 million. Kamada reported $0.06 EPS, missing estimates, and declared a $0.25 dividend. Institutional ownership stands at 20.38%. Analysts have a consensus rating of "Moderate Buy" with a target price of $13.00.

Kamada(KMDA.US)

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory

Kamada shares are trading lower after the company reported worse-than-expected Q1 financial results.

Veritone Q1 2026 Earnings Call: Complete Transcript

Kamada Q1 2026 earnings preview

Kamada Ltd. (NASDAQ:KMDA) Short Interest Update